NEXUS BIOPHARMA INC: 10-Q filed 2016-10-24
What NEXUS BIOPHARMA INC reported in its quarterly report filed 2016-10-24 (fiscal Q2 2017): 16 published measures, 39 facts as tagged in accession 0001213900-16-017692.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-10-24
- Fiscal period
- fiscal Q2 2017
- Accession
- 0001213900-16-017692 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All NEXUS BIOPHARMA INC filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-08-31 | 70,211 | USD | |
| At 2016-02-29 | 9,925 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-08-31 | 1,276,922 | USD | |
| At 2016-02-29 | 776,717 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-08-31 | 62,441 | USD | |
| At 2016-02-29 | 9,925 | USD | |
| At 2015-02-28 | 22,052 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-06-01 to 2016-08-31 | -179,340 | USD | 92 |
| 2016-03-01 to 2016-08-31 | -438,998 | USD | 184 |
| 2015-06-01 to 2015-08-31 | -768,722 | USD | 92 |
| 2015-03-01 to 2015-08-31 | -914,173 | USD | 184 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-08-31 | -3,047,345 | USD | |
| At 2016-02-29 | -2,608,347 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-03-01 to 2016-08-31 | 91,800 | USD | 184 |
| 2015-03-01 to 2015-08-31 | 625,000 | USD | 184 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-08-31 | 62,441 | USD | |
| At 2016-02-29 | 9,925 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-08-31 | 1,232,477 | USD | |
| At 2016-02-29 | 735,606 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-08-31 | 100,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-06-01 to 2016-08-31 | 170,307 | USD | 92 |
| 2016-03-01 to 2016-08-31 | 425,821 | USD | 184 |
| 2015-06-01 to 2015-08-31 | 768,722 | USD | 92 |
| 2015-03-01 to 2015-08-31 | 914,173 | USD | 184 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-06-01 to 2016-08-31 | 8,904 | USD | 92 |
| 2016-03-01 to 2016-08-31 | 16,404 | USD | 184 |
| 2015-06-01 to 2015-08-31 | 7,500 | USD | 92 |
| 2015-03-01 to 2015-08-31 | 110,900 | USD | 184 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-08-31 | 64,309,655 | shares | |
| At 2016-02-29 | 31,552,524 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-08-31 | 1,839,991 | USD | |
| At 2016-02-29 | 1,841,240 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-08-31 | -1,206,711 | USD | |
| At 2016-02-29 | -766,792 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-08-31 | 7,770 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-06-01 to 2016-08-31 | 161,403 | USD | 92 |
| 2016-03-01 to 2016-08-31 | 409,417 | USD | 184 |
| 2015-06-01 to 2015-08-31 | 761,222 | USD | 92 |
| 2015-03-01 to 2015-08-31 | 803,273 | USD | 184 |
Inspect the source
- Entity
- NEXUS BIOPHARMA INC / CIK 0001424151
- Captured
- SEC response SHA-256
81b0df49b134712b3ab491313fca6e4fc63ab10b540bae43257eb936c9a8216c
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001424151.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))